Background: Soft tissue sarcomas (STS) comprise over 150 histological subtypes, with advanced cases showing poor prognosis (5-year survival <10%). Trabectedin, a synthetic alkaloid, is frequently used after anthracycline-based chemotherapy failure. Despite the withdrawal of reimbursement in France in 2018 due to debated efficacy and safety, it remains in clinical use, imposing financial strain on hospitals. Methods: This retrospective single-center study evaluated trabectedin's efficacy, safety, and cost in 68 patients treated between 2019 and 2023. Results: L-sarcomas accounted for 78% of cases, including uterine leiomyosarcomas (n=16), soft-tissue leiomyosarcomas (n=17), and myxoid liposarcomas (n=8). Non-L-sarcomas (22%) included mostly synovial sarcomas. The overall disease control rate was 71%, with a median progression-free survival (PFS) of 4.1 months. Subtype-specific median PFS was 6.8 months for liposarcomas (11.3 for myxoid vs. 4.5 for other subtypes), 3.1 months for leiomyosarcomas (3.4 months for uterine vs 3.1 for soft-tissue), and 2.4 months for non-L-sarcomas. Patients received a median of 5 cycles (range: 1;38), with an average total dose of 16 mg 2;81, and an average hospital cost of 9,900 euros. Adverse events occurred in 91%, mainly hematological; cardiac toxicity was seen in 9%. Conclusion: Despite limited reimbursement, trabectedin remains a relevant treatment, particularly in L-sarcoma management.
Giraud et al. (Wed,) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: